MetaCap

Immutep (IMMP) vs Incannex Healthcare (IXHL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immutep (IMMP) has outperformed Incannex Healthcare (IXHL) over the past year, gaining 80.8% versus a loss of 80.3%. Incannex Healthcare is the larger company by market cap ($23.3 million vs $22.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMMP+80.81%IXHL-80.32%
+375%+134%-107%
Nov 21, 20251 yearNov 20, 2026
IMMP+13.09%IXHL-99.88%
+198%+42%-114%
Feb 28, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMMP versus IXHL key metrics
MetricIMMPIXHL
Share price$3.11$1.86
Market cap$22.92M$23.34M
1-day change-9.06%+6.90%
YTD return+8.74%-82.68%
1-year return+80.81%-80.32%
5-year return-8.53%—
EPS (TTM)$-7.30$-1.25
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)—$-19.30M
52-week high$70.60$14.91
52-week low$2.66$1.61
Distance from 52-week high-95.59%-87.53%
Analyst consensusnonestrong_buy
Avg. price target upside+864.63%+904.30%
Average volume26.07K91.61K
Shares outstanding7.37M12.55M
Employees—12
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMMP has outperformed IXHL by 161.1 percentage points over the past year.

About Immutep

IMMP stock →

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations

About Incannex Healthcare

IXHL stock →

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

IMMP vs IXHL FAQ

Which is bigger, Immutep or Incannex Healthcare?

Incannex Healthcare (IXHL) is larger, with a market capitalization of $23.34M compared with $22.92M for Immutep (IMMP).

Which stock has performed better over the past year, IMMP or IXHL?

IMMP returned +80.81% over the past 12 months, compared with -80.32% for IXHL (price return, excluding dividends). Past performance does not predict future results.

Are Immutep and Incannex Healthcare in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons